SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 289.14 |
| Enterprise Value ($M) | 278.66 |
| Book Value ($M) | 113.44 |
| Book Value / Share | 1.96 |
| Price / Book | 2.55 |
| NCAV ($M) | 100.20 |
| NCAV / Share | 1.73 |
| Price / NCAV | 2.89 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.60 |
| Return on Assets (ROA) | -0.61 |
| Return on Equity (ROE) | -0.67 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.79 |
| Current Ratio | 13.79 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 110.18 |
| Assets | 123.41 |
| Liabilities | 9.97 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -70.42 |
| Net Income | -68.46 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -57.37 |
| Cash from Investing | 48.70 |
| Cash from Financing | 63.03 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vivo Opportunity Fund Holdings, L.P. | 4.80 | -13.73 | |
| 13G/A | First Manhattan Co | 0.00 | -100.00 | |
| 13G/A | Stonepine Capital Management, LLC | 0.00 | -100.00 | |
| 13G/A | Adage Capital Management, L.P. | 4.91 | ||
| 13G | Nantahala Capital Management, LLC | 9.90 | ||
| 13G/A | Federated Hermes, Inc. | 19.99 | 9.27 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 26,552 | 187,183 | 14.19 | |
| 80,721 | 391,484 | 20.62 | |
| 30,899 | 162,083 | 19.06 | |
| 61,450 | 232,822 | 26.39 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RNAZ – TransCode Therapeutics, Inc. | RNXT – RenovoRx, Inc. |
| RVPH – Reviva Pharmaceuticals Holdings, Inc. | SABS – SAB Biotherapeutics, Inc. |
| SAVA – Cassava Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io